Helen S Marshall

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8388339/publications.pdf

Version: 2024-02-01

184 papers 5,684 citations

93792 39 h-index 65 g-index

186 all docs

186 docs citations

186 times ranked 6222 citing authors

#	Article	IF	CITATIONS
1	A rapid global review of strategies to improve influenza vaccination uptake in Australia. Human Vaccines and Immunotherapeutics, 2024, 17, 5487-5499.	1.4	5
2	Immunisation with the BCG and DTPw vaccines induces different programs of trained immunity in mice. Vaccine, 2022, 40, 1594-1605.	1.7	6
3	B Part of It School Leaver Study: A Repeat Cross-Sectional Study to Assess the Impact of Increasing Coverage With Meningococcal B (4CMenB) Vaccine on Carriage of <i>Neisseria meningitidis</i> Journal of Infectious Diseases, 2022, 225, 637-649.	1.9	5
4	Pertussis Disease and Antenatal Vaccine Effectiveness in Australian Children. Pediatric Infectious Disease Journal, 2022, 41, 180-185.	1.1	6
5	4CMenB vaccine and its role in preventing transmission and inducing herd immunity. Expert Review of Vaccines, 2022, 21, 103-114.	2.0	7
6	Influenza hospitalizations in Australian children 2010–2019: The impact of medical comorbidities on outcomes, vaccine coverage, and effectiveness. Influenza and Other Respiratory Viruses, 2022, 16, 316-327.	1.5	7
7	Q fever prevention: Perspectives from university animal science and veterinary students and livestock farmers. Australian Journal of Rural Health, 2022, 30, 385-392.	0.7	3
8	Using provider–parent strategies to improve influenza vaccination in children and adolescents with special risk medical conditions: a randomised controlled trial protocol. BMJ Open, 2022, 12, e053838.	0.8	2
9	Surveillance for severe influenza and COVID-19 in patients admitted to sentinel Australian hospitals in 2020: the Influenza Complications Alert Network (FluCAN). Communicable Diseases Intelligence (2018), 2022, 45, .	0.3	2
10	An Observational Study to Assess the Effectiveness of 4CMenB against Meningococcal Disease and Carriage and Gonorrhea in Adolescents in the Northern Territory, Australia—Study Protocol. Vaccines, 2022, 10, 309.	2.1	3
11	Severity of Rotavirus-Vaccine-Associated Intussusception: Prospective Hospital-Based Surveillance, Australia, 2007–2018. Pediatric Infectious Disease Journal, 2022, 41, 507-513.	1.1	5
12	Q fever prevention in Australia: general practitioner and stakeholder perspectives on preparedness and the potential of a One Health approach. Australian and New Zealand Journal of Public Health, 2022, 46, 196-202.	0.8	2
13	Effectiveness and impact of the 4CMenB vaccine against invasive serogroup B meningococcal disease and gonorrhoea in an infant, child, and adolescent programme: an observational cohort and case-control study. Lancet Infectious Diseases, The, 2022, 22, 1011-1020.	4.6	40
14	Influenza epidemiology in patients admitted to sentinel Australian hospitals in 2019: the Influenza Complications Alert Network FluCAN. Communicable Diseases Intelligence (2018), 2022, 46, .	0.3	0
15	Postinfectious Acute Cerebellar Syndromes in Children: A Nationally Ascertained Case Series From Australia 2013–2018. Journal of Child Neurology, 2022, , 088307382210932.	0.7	1
16	COVID-19 vaccine willingness prior to and during the COVID-19 vaccination rollout in Australia. Human Vaccines and Immunotherapeutics, 2022, 18, .	1.4	8
17	Effectiveness of Meningococcal Vaccines at Reducing Invasive Meningococcal Disease and Pharyngeal <i>Neisseria meningitidis</i> Carriage: A Systematic Review and Meta-analysis. Clinical Infectious Diseases, 2021, 73, e609-e619.	2.9	33
18	Impact of Meningococcal B (4CMenB) Vaccine on Pharyngeal Neisseria meningitidis Carriage Density and Persistence in Adolescents. Clinical Infectious Diseases, 2021, 73, e99-e106.	2.9	18

#	Article	IF	CITATIONS
19	Barriers to influenza vaccination of children hospitalised for acute respiratory illness: A crossâ€sectional survey. Journal of Paediatrics and Child Health, 2021, 57, 409-418.	0.4	7
20	Safety of maternal pertussis vaccination on pregnancy and birth outcomes: A prospective cohort study. Vaccine, 2021, 39, 324-331.	1.7	9
21	Q fever vaccination: Australian animal science and veterinary students' One Health perspectives on Q fever prevention. Human Vaccines and Immunotherapeutics, 2021, 17, 1374-1381.	1.4	5
22	Assessing the impact of the 13 valent pneumococcal vaccine on childhood empyema in Australia. Thorax, 2021, 76, 487-493.	2.7	13
23	Impact of Meningococcal B Vaccine on Invasive Meningococcal Disease in Adolescents. Clinical Infectious Diseases, 2021, 73, e233-e237.	2.9	22
24	The Collaboration for Increasing Influenza Vaccination in Children (CIIVIC): a meeting report. Australian and New Zealand Journal of Public Health, 2021, 45, 193-196.	0.8	2
25	Q fever prevention and vaccination: Australian livestock farmers' knowledge and attitudes to inform a One Health approach. One Health, 2021, 12, 100232.	1.5	8
26	School-based HPV vaccination positively impacts parents' attitudes toward adolescent vaccination. Vaccine, 2021, 39, 4190-4198.	1.7	20
27	Recent advances in meningococcal B disease prevention: real-world evidence from 4CMenB vaccination. Journal of Infection, 2021, 83, 17-26.	1.7	26
28	Lessons for and from the COVID-19 pandemic response â€" An appraisal of guidance for the public health management of Invasive Meningococcal Disease. Journal of Infection and Public Health, 2021, 14, 1069-1074.	1.9	2
29	Body mass index and vaccine responses following influenza vaccination during pregnancy. Vaccine, 2021, 39, 4864-4870.	1.7	3
30	National predictors of influenza vaccine uptake in pregnancy: the FluMum prospective cohort study, Australia, 2012–2015. Australian and New Zealand Journal of Public Health, 2021, 45, 455-461.	0.8	9
31	Social and behavioral predictors of two-doses 4CMenB vaccine series among adolescents enrolled in a cluster randomized controlled trial in Australia. Human Vaccines and Immunotherapeutics, 2021, , 1-9.	1.4	0
32	Paediatric Active Enhanced Disease Surveillance (PAEDS) 2019: Prospective hospital-based surveillance for serious paediatric conditions. Communicable Diseases Intelligence (2018), 2021, 45, .	0.3	7
33	Evaluating the effectiveness of the 4CMenB vaccine against invasive meningococcal disease and gonorrhoea in an infant, child and adolescent program: protocol. Human Vaccines and Immunotherapeutics, 2021, 17, 1450-1454.	1.4	8
34	Intracluster correlation coefficients in a large cluster randomized vaccine trial in schools: Transmission and impact of shared characteristics. PLoS ONE, 2021, 16, e0254330.	1.1	0
35	Meningococcal surveillance in Southeast Asia and the Pacific. Microbiology Australia, 2021, 42, 178-181.	0.1	3
36	Prospective characterisation of SARS-CoV-2 infections among children presenting to tertiary paediatric hospitals across Australia in 2020: a national cohort study. BMJ Open, 2021, 11, e054510.	0.8	14

#	Article	IF	Citations
37	Effect of a School-Based Educational Intervention About the Human Papillomavirus Vaccine on Psychosocial Outcomes Among Adolescents. JAMA Network Open, 2021, 4, e2129057.	2.8	12
38	Study Protocol for Preventing Early-Onset Pneumonia in Young Children Through Maternal Immunisation: A Multi-Centre Randomised Controlled Trial (PneuMatters). Frontiers in Pediatrics, 2021, 9, 781168.	0.9	2
39	Causes and Clinical Features of Childhood Encephalitis: A Multicenter, Prospective Cohort Study. Clinical Infectious Diseases, 2020, 70, 2517-2526.	2.9	48
40	Spatial, temporal, and occupational risks of Q fever infection in South Australia, 2007–2017. Journal of Infection and Public Health, 2020, 13, 544-551.	1.9	8
41	First statewide meningococcal B vaccine program in infants, children and adolescents: evidence for implementation in South Australia. Medical Journal of Australia, 2020, 212, 89-93.	0.8	16
42	The potential for improved protection against pertussis. Lancet Infectious Diseases, The, 2020, 20, 1220-1222.	4.6	1
43	Meningococcal disease surveillance in the Asia–Pacific region (2020): The global meningococcal initiative. Journal of Infection, 2020, 81, 698-711.	1.7	51
44	Care of the patient with invasive meningococcal disease by prehospital emergency medical service clinicians: a scoping review. BMJ Open, 2020, 10, e033447.	0.8	4
45	Impact of a Meningococcal Protein-based Serogroup B Vaccine on Serogroup W Invasive Disease in Children. Clinical Infectious Diseases, 2020, 73, e1669-e1672.	2.9	2
46	Influenza vaccination: A qualitative study of practice level barriers from medical practitioners caring for children with special risk medical conditions. Vaccine, 2020, 38, 7806-7814.	1.7	5
47	The everchanging epidemiology of meningococcal disease worldwide and the potential for prevention through vaccination. Journal of Infection, 2020, 81, 483-498.	1.7	133
48	Feasibility and acceptability of the multi-component P3-MumBubVax antenatal intervention to promote maternal and childhood vaccination: A pilot study. Vaccine, 2020, 38, 4024-4031.	1.7	20
49	Seasonal influenza vaccination for children with special risk medical conditions: Does policy meet practice?. Journal of Paediatrics and Child Health, 2020, 56, 1388-1395.	0.4	5
50	Psychosocial determinants of pertussis and influenza vaccine uptake in pregnant women: A prospective study. Vaccine, 2020, 38, 3358-3368.	1.7	19
51	The impact of new universal child influenza programs in Australia: Vaccine coverage, effectiveness and disease epidemiology in hospitalised children in 2018. Vaccine, 2020, 38, 2779-2787.	1.7	24
52	Meningococcal B Vaccine and Meningococcal Carriage in Adolescents in Australia. New England Journal of Medicine, 2020, 382, 318-327.	13.9	133
53	Clinical Description and Outcomes of Australian Children With Invasive Group A Streptococcal Disease. Pediatric Infectious Disease Journal, 2020, 39, 379-384.	1.1	7
54	Disparities in parental awareness of children's seasonal influenza vaccination recommendations and influencers of vaccination. PLoS ONE, 2020, 15, e0230425.	1.1	11

#	Article	IF	CITATIONS
55	Active surveillance of acute paediatric hospitalisations demonstrates the impact of vaccination programmes and informs vaccine policy in Canada and Australia. Eurosurveillance, 2020, 25, .	3.9	8
56	Scientific evidence supporting recommendations on the use of the 9-valent HPV vaccine in a 2-dose vaccine schedule in Australia. Communicable Diseases Intelligence (2018), 2020, 44, .	0.3	6
57	Paediatric Active Enhanced Disease Surveillance (PAEDS) 2017 and 2018: Prospective hospital-based surveillance for serious paediatric conditions. Communicable Diseases Intelligence (2018), 2020, 44, .	0.3	8
58	Influenza Epidemiology, Vaccine Coverage and Vaccine Effectiveness in Children Admitted to Sentinel Australian Hospitals in 2017: Results from the PAEDS-FluCAN Collaboration. Clinical Infectious Diseases, 2019, 68, 940-948.	2.9	46
59	Long term follow up of persistence of immunity following quadrivalent Human Papillomavirus (HPV) vaccine in immunocompromised children. Vaccine, 2019, 37, 5630-5636.	1.7	11
60	Relationship between birth weight or fetal growth rate and postnatal allergy: AÂsystematic review. Journal of Allergy and Clinical Immunology, 2019, 144, 1703-1713.	1.5	18
61	Lifetime costs of invasive meningococcal disease: A Markov model approach. Vaccine, 2019, 37, 6885-6893.	1.7	8
62	S. aureus colonization in healthy Australian adults receiving an investigational S. aureus 3-antigen vaccine. Journal of Infection, 2019, 79, 582-592.	1.7	3
63	Attitudes about and access to influenza vaccination experienced by parents of children hospitalised for influenza in Australia. Vaccine, 2019, 37, 5994-6001.	1.7	15
64	Are children with special risk medical conditions receiving influenza vaccination? Validity of parental and provider report, and to a National Immunisation Register. Human Vaccines and Immunotherapeutics, 2019, 15, 951-958.	1.4	4
65	B Part of It School Leaver protocol: an observational repeat cross-sectional study to assess the impact of a meningococcal serogroup B (4CMenB) vaccine programme on carriage of $\langle i \rangle$ Neisseria meningitidis $\langle i \rangle$. BMJ Open, 2019, 9, e027233.	0.8	8
66	Burden of varicella in the Asia-Pacific region: a systematic literature review. Expert Review of Vaccines, 2019, 18, 475-493.	2.0	19
67	Is a One Health Approach Utilized for Q Fever Control? A Comprehensive Literature Review. International Journal of Environmental Research and Public Health, 2019, 16, 730.	1.2	36
68	Case fatality rates of invasive meningococcal disease by serogroup and age: A systematic review and meta-analysis. Vaccine, 2019, 37, 2768-2782.	1.7	121
69	A systematic review of interventions to improve uptake of pertussis vaccination in pregnancy. PLoS ONE, 2019, 14, e0214538.	1.1	30
70	AMEND study protocol: a case–control study to assess the long-term impact of invasive meningococcal disease in Australian adolescents and young adults. BMJ Open, 2019, 9, e032583.	0.8	3
71	Invasive group A Streptococcus disease in Australian children: 2016 to 2018 – a descriptive cohort study. BMC Public Health, 2019, 19, 1750.	1.2	29
72	Influenza in Children With Special Risk Medical Conditions. Pediatric Infectious Disease Journal, 2019, 38, 912-919.	1.1	16

#	Article	IF	CITATIONS
73	Immunogenicity and Safety of a Quadrivalent Meningococcal ACWY-tetanus Toxoid Conjugate Vaccine 6 Years After MenC Priming as Toddlers. Pediatric Infectious Disease Journal, 2019, 38, 643-650.	1.1	6
74	Severe and Complicated Varicella and Associated Genotypes 10 Years After Introduction of a One-Dose Varicella Vaccine Program. Journal of Infectious Diseases, 2019, 219, 391-399.	1.9	5
75	The changing epidemiology of mumps in a high vaccination era. Lancet Infectious Diseases, The, 2019, 19, 118-119.	4.6	20
76	The Safety of Influenza and Pertussis Vaccination in Pregnancy in a Cohort of Australian Mother-Infant Pairs, 2012–2015: The FluMum Study. Clinical Infectious Diseases, 2019, 68, 402-408.	2.9	31
77	B Part of It study: a longitudinal study to assess carriage of <i>Neisseria meningitidis</i> in first year university students in South Australia. Human Vaccines and Immunotherapeutics, 2019, 15, 987-994.	1.4	28
78	Varicella vaccine effectiveness over 10 years in Australia; moderate protection from 1-dose program. Journal of Infection, 2019, 78, 220-225.	1.7	18
79	Severe Respiratory Syncytial Virus Infection in Hospitalized Children Less Than 3 Years of Age in a Temperate and Tropical Climate. Pediatric Infectious Disease Journal, 2019, 38, 6-11.	1.1	10
80	Antibody persistence and booster response in adolescents and young adults 4 and 7.5 years after immunization with 4CMenB vaccine. Vaccine, 2019, 37, 1209-1218.	1.7	33
81	Paediatric Active Enhanced Disease Surveillance (PAEDS) annual report 2016: Prospective hospital-based surveillance for serious paediatric conditions. Communicable Diseases Intelligence (2018), 2019, 43, .	0.3	4
82	Immunogenicity and safety of one or two doses of the quadrivalent meningococcal vaccine MenACWY-TT given alone or with the 13-valent pneumococcal conjugate vaccine in toddlers: A phase III, open-label, randomised study. Vaccine, 2018, 36, 1908-1916.	1.7	17
83	Vaccine hesitancy, refusal and access barriers: The need for clarity in terminology. Vaccine, 2018, 36, 6556-6558.	1.7	224
84	Influenza vaccination: Uptake and associations in a cross-sectional study of children with special risk medical conditions. Vaccine, 2018, 36, 8138-8147.	1.7	20
85	Immunogenicity and Safety of Monovalent Acellular Pertussis Vaccine at Birth. JAMA Pediatrics, 2018, 172, 1045.	3.3	34
86	Costs of Invasive Meningococcal Disease: A Global Systematic Review. Pharmacoeconomics, 2018, 36, 1201-1222.	1.7	22
87	Factors associated with uptake of influenza and pertussis vaccines among pregnant women in South Australia. PLoS ONE, 2018, 13, e0197867.	1.1	53
88	B Part of It protocol: a cluster randomised controlled trial to assess the impact of 4CMenB vaccine on pharyngeal carriage of <i>Neisseria meningitidis </i> in adolescents. BMJ Open, 2018, 8, e020988.	0.8	28
89	The impact of 10 years of human papillomavirus (HPV) vaccination in Australia: what additional disease burden will a nonavalent vaccine prevent?. Eurosurveillance, 2018, 23, .	3.9	179
90	Birth outcomes for Australian mother-infant pairs who received an influenza vaccine during pregnancy, 2012–2014: The FluMum study. Vaccine, 2017, 35, 1403-1409.	1.7	25

#	Article	IF	CITATIONS
91	Safety of Tetanus, Diphtheria, and Pertussis Vaccination During Pregnancy. Obstetrics and Gynecology, 2017, 129, 560-573.	1.2	82
92	Vaccine discussions with parents: The experience of Australian paediatricians. Journal of Paediatrics and Child Health, 2017, 53, 855-861.	0.4	12
93	Influenza epidemiology and immunization during pregnancy: Final report of a World Health Organization working group. Vaccine, 2017, 35, 5738-5750.	1.7	75
94	The Spectrum and Burden of Influenza-Associated Neurological Disease in Children: Combined Encephalitis and Influenza Sentinel Site Surveillance From Australia, 2013–2015. Clinical Infectious Diseases, 2017, 65, 653-660.	2.9	82
95	Congenital microcephaly: Case definition & Equipment of the Congenital microcephaly: Case definition & Case defini	1.7	46
96	Influenza-associated Encephalitis/Encephalopathy Identified by the Australian Childhood Encephalitis Study 2013–2015. Pediatric Infectious Disease Journal, 2017, 36, 1021-1026.	1.1	48
97	Incidence of influenza virus infection among pregnant women: a systematic review. BMC Pregnancy and Childbirth, 2017, 17, 155.	0.9	38
98	Meningococcal serogroup B-specific responses after vaccination with bivalent rLP2086: 4 year follow-up of a randomised, single-blind, placebo-controlled, phase 2 trial. Lancet Infectious Diseases, The, 2017, 17, 58-67.	4.6	33
99	Respiratory distress in the neonate: Case definition & Early; guidelines for data collection, analysis, and presentation of maternal immunization safety data. Vaccine, 2017, 35, 6506-6517.	1.7	38
100	Adolescent values for immunisation programs in Australia: A discrete choice experiment. PLoS ONE, 2017, 12, e0181073.	1.1	21
101	Control of invasive meningococcal disease. International Journal of Evidence-Based Healthcare, 2016, 14, 3-14.	0.1	10
102	Understanding motivators and barriers of hospital-based obstetric and pediatric health care worker influenza vaccination programs in Australia. Human Vaccines and Immunotherapeutics, 2016, 12, 1-8.	1.4	11
103	Prioritizing government funding of adolescent vaccinations: recommendations from young people on a citizens' jury. Vaccine, 2016, 34, 3592-3597.	1.7	8
104	Safety and immunogenicity of a booster dose of a 3-antigen Staphylococcus aureus vaccine (SA3Ag) in healthy adults: A randomized phase 1 study. Journal of Infection, 2016, 73, 437-454.	1.7	11
105	Congenital anomalies: Case definition and guidelines for data collection, analysis, and presentation of immunization safety data. Vaccine, 2016, 34, 6015-6026.	1.7	74
106	Efficacy of a trivalent influenza vaccine against seasonal strains and against 2009 pandemic H1N1: A randomized, placebo-controlled trial. Vaccine, 2016, 34, 4991-4997.	1.7	11
107	Adolescent confidence in immunisation: Assessing and comparing attitudes of adolescents and adults. Vaccine, 2016, 34, 5595-5603.	1.7	11
108	Retrospective review of factors associated with severe hospitalised communityâ€acquired influenza in a tertiary paediatric hospital in South Australia. Influenza and Other Respiratory Viruses, 2016, 10, 479-485.	1.5	6

#	Article	IF	CITATIONS
109	Immunogenicity and persistence of immunity of a quadrivalent Human Papillomavirus (HPV) vaccine in immunocompromised children. Vaccine, 2016, 34, 4343-4350.	1.7	23
110	Development of a human papillomavirus vaccination intervention for Australian adolescents. Health Education Journal, 2016, 75, 610-620.	0.6	10
111	Better colonisation of newly emerged Bordetella pertussis in the co-infection mouse model study. Vaccine, 2016, 34, 3967-3971.	1.7	40
112	Intersectoral collaboration to implement school-based health programmes: Australian perspectives. Health Promotion International, 2016, 32, dav120.	0.9	28
113	Genomic dissection of Australian Bordetella pertussis isolates from the 2008–2012 epidemic. Journal of Infection, 2016, 72, 468-477.	1.7	52
114	Should professionals caring for children be vaccinated? Community perspectives on health care and child care worker immunisation. Vaccine, 2016, 34, 1726-1732.	1.7	4
115	The relationship between Bordetella pertussis genotype and clinical severity in Australian children with pertussis. Journal of Infection, 2016, 72, 171-178.	1.7	32
116	Seeking Community Views on Allocation of Scarce Resources in a Pandemic in Australia: Two Methods, Two Answers. The International Library of Ethics, Law and Technology, 2016, , 245-261.	0.2	0
117	Community awareness and predictors of uptake of pertussis booster vaccine in South Australian adults. Vaccine, 2015, 33, 7337-7343.	1.7	6
118	HPV.edu study protocol: a cluster randomised controlled evaluation of education, decisional support and logistical strategies in school-based human papillomavirus (HPV) vaccination of adolescents. BMC Public Health, 2015, 15, 896.	1.2	17
119	Ethical Challenges in School-Based Immunization Programs for Adolescents: A Qualitative Study. American Journal of Public Health, 2015, 105, 1399-1403.	1.5	16
120	Group A Streptococcal Carriage and Seroepidemiology in Children up to 10 Years of Age in Australia. Pediatric Infectious Disease Journal, 2015, 34, 831-838.	1.1	15
121	Five-year Antibody Persistence and Safety After a Single Dose of Combined Haemophilus influenzae Type B Neisseria meningitidis Serogroup C–Tetanus Toxoid Conjugate Vaccine in Haemophilus influenzae Type B-primed Toddlers. Pediatric Infectious Disease Journal, 2015, 34, 1379-1384.	1.1	4
122	Febrile seizures following measles and varicella vaccines in young children in Australia. Vaccine, 2015, 33, 1412-1417.	1.7	23
123	Immune responses to a recombinant, four-component, meningococcal serogroup B vaccine (4CMenB) in adolescents: A phase III, randomized, multicentre, lot-to-lot consistency study. Vaccine, 2015, 33, 5217-5224.	1.7	37
124	Barriers to childhood immunisation: Findings from the Longitudinal Study of Australian Children. Vaccine, 2015, 33, 3377-3383.	1.7	58
125	A randomized phase I study of the safety and immunogenicity of three ascending dose levels of a 3-antigen Staphylococcus aureus vaccine (SA3Ag) in healthy adults. Vaccine, 2015, 33, 1846-1854.	1.7	56
126	Predictors of Disease Severity in Children Hospitalized for Pertussis During an Epidemic. Pediatric Infectious Disease Journal, 2015, 34, 339-345.	1.1	48

#	Article	IF	CITATIONS
127	Factors affecting uptake of recommended immunizations among health care workers in South Australia. Human Vaccines and Immunotherapeutics, 2015, 11, 704-712.	1.4	28
128	Pertactin negative Bordetella pertussis demonstrates higher fitness under vaccine selection pressure in a mixed infection model. Vaccine, 2015, 33, 6277-6281.	1.7	93
129	Consumer reporting of adverse events following immunization (AEFI). Human Vaccines and Immunotherapeutics, 2014, 10, 747-754.	1.4	14
130	FluMum: a prospective cohort study of mother-infant pairs assessing the effectiveness of maternal influenza vaccination in prevention of influenza in early infancy. BMJ Open, 2014, 4, e005676-e005676.	0.8	14
131	Rapid Increase in Pertactin-deficient <i>Bordetella pertussis</i> li>Isolates, Australia. Emerging Infectious Diseases, 2014, 20, 626-33.	2.0	151
132	Incorporating immunizations into routine obstetric care to facilitate Health Care Practitioners in implementing maternal immunization recommendations. Human Vaccines and Immunotherapeutics, 2014, 10, 1114-1121.	1.4	32
133	Antibody and Cell-mediated Immunity to Pertussis 4 Years After Monovalent Acellular Pertussis Vaccine at Birth. Pediatric Infectious Disease Journal, 2014, 33, 511-517.	1.1	10
134	Heterologous Prime-Boost Vaccination Using an ASO3B-Adjuvanted Influenza A(H5N1) Vaccine in Infants and Children <3 Years of Age. Journal of Infectious Diseases, 2014, 210, 1800-1810.	1.9	17
135	Clinical epidemiology and predictors of outcome in children hospitalised with influenza A(H1N1)pdm09 in 2009: a prospective national study. Influenza and Other Respiratory Viruses, 2014, 8, 636-645.	1.5	24
136	Community, parental and adolescent awareness and knowledge of meningococcal disease. Vaccine, 2014, 32, 2042-2049.	1.7	23
137	The inpatient costs and hospital service use associated with invasive meningococcal disease in South Australian children. Vaccine, 2014, 32, 4791-4798.	1.7	31
138	Parental and community acceptance of the benefits and risks associated with meningococcal B vaccines. Vaccine, 2014, 32, 338-344.	1.7	32
139	Eliciting youth and adult recommendations through citizens' juries to improve school based adolescent immunisation programs. Vaccine, 2014, 32, 2434-2440.	1.7	19
140	The missing link: Family physician perspectives on barriers and enablers to prescribing a new Meningococcal B vaccine and other recommended, non-government funded vaccines. Vaccine, 2014, 32, 4214-4219.	1.7	11
141	The Clinical Burden And Predictors of Sequelae Following Invasive Meningococcal Disease In Australian Children. Pediatric Infectious Disease Journal, 2014, 33, 316-318.	1.1	25
142	Interventions for increasing the uptake of immunisation in healthcare workers. The Cochrane Library, 2014, , .	1.5	0
143	Understanding the school community's response to school closures during the H1N1 2009 influenza pandemic. BMC Public Health, 2013, 13, 344.	1.2	122
144	Parental and societal support for adolescent immunization through school based immunization programs. Vaccine, 2013, 31, 3059-3064.	1.7	11

#	Article	IF	CITATIONS
145	Parental perspectives of vaccine safety and experience of adverse events following immunisation. Vaccine, 2013, 31, 2067-2074.	1.7	38
146	Healthcare providers' knowledge, experience and challenges of reporting adverse events following immunisation: a qualitative study. BMC Health Services Research, 2013, 13, 313.	0.9	41
147	A phase 2 open-label safety and immunogenicity study of a meningococcal B bivalent rLP2086 vaccine in healthy adults. Vaccine, 2013, 31, 1569-1575.	1.7	73
148	Three-year Antibody Persistence and Safety After a Single Dose of Combined Haemophilus influenzae Type b (Hib)–Neisseria meningitidis Serogroup C-tetanus Toxoid Conjugate Vaccine in Hib-primed Toddlers. Pediatric Infectious Disease Journal, 2013, 32, 169-174.	1.1	9
149	Safety and tolerability of a 2009 trivalent inactivated split-virion influenza vaccine in infants, children and adolescents. Influenza and Other Respiratory Viruses, 2013, 7, 676-685.	1.5	18
150	Community knowledge, behaviours and attitudes about the 2009 H1N1 Influenza pandemic: a systematic review. Influenza and Other Respiratory Viruses, 2013, 7, 1316-1327.	1.5	55
151	A Randomized, Controlled, Phase 1/2 Trial of a Neisseria meningitidis Serogroup B Bivalent rLP2086 Vaccine in Healthy Children and Adolescents. Pediatric Infectious Disease Journal, 2013, 32, 364-371.	1.1	54
152	Changes in Patterns of Hospitalized Children With Varicella and of Associated Varicella Genotypes After Introduction of Varicella Vaccine in Australia. Pediatric Infectious Disease Journal, 2013, 32, 530-537.	1.1	34
153	Parental views on vaccine safety and future vaccinations of children who experienced an adverse event following routine or seasonal influenza vaccination in 2010. Human Vaccines and Immunotherapeutics, 2012, 8, 662-667.	1.4	19
154	Immunogenicity and safety of measles-mumps-rubella and varicella vaccines coadministered with a fourth dose of <i>Haemophilus influenzae</i> type b and <i>Neisseria meningitidis</i> serogroups C and Y-tetanus toxoid conjugate vaccine in toddlers. Human Vaccines and Immunotherapeutics, 2012, 8, 1036-1041.	1.4	10
155	Neurologic complications of influenza A(H1N1)pdm09. Neurology, 2012, 79, 1474-1481.	1.5	79
156	A Randomized Trial to Assess Safety and Immunogenicity of Alternative Formulations of a Quadrivalent Meningococcal (A, C, Y, and W-135) Tetanus Protein Conjugate Vaccine in Toddlers. Pediatric Infectious Disease Journal, 2012, 31, e15-e23.	1.1	13
157	A qualitative study investigating knowledge and attitudes regarding human papillomavirus (HPV) and the HPV vaccine among parents of immunosuppressed children. Vaccine, 2012, 30, 7027-7031.	1.7	9
158	Safety, immunogenicity, and tolerability of meningococcal serogroup B bivalent recombinant lipoprotein 2086 vaccine in healthy adolescents: a randomised, single-blind, placebo-controlled, phase 2 trial. Lancet Infectious Diseases, The, 2012, 12, 597-607.	4.6	120
159	Factors associated with HPV vaccine uptake in teenage girls: A systematic review. Vaccine, 2012, 30, 3546-3556.	1.7	362
160	Awareness, anxiety, compliance: Community perceptions and response to the threat and reality of an influenza pandemic. American Journal of Infection Control, 2012, 40, 270-272.	1.1	17
161	Safety and Immunogenicity of a Meningococcal B Bivalent rLP2086 Vaccine in Healthy Toddlers Aged 18–36 Months. Pediatric Infectious Disease Journal, 2012, 31, 1061-1068.	1.1	57
162	Recurrence of extensive injection site reactions following DTPa or dTpa vaccine in children 4–6 years old. Vaccine, 2011, 29, 4230-4237.	1.7	20

#	Article	IF	CITATIONS
163	Direct and indirect impact on rotavirus positive and all-cause gastroenteritis hospitalisations in South Australian children following the introduction of rotavirus vaccination. Vaccine, 2011, 29, 4663-4667.	1.7	52
164	IMMEDIATE AND LONGER TERM IMMUNOGENICITY OF A SINGLE DOSE OF THE COMBINED HAEMOPHILUS INFLUENZAE TYPE B-NEISSERIA MENINGITIDIS SEROGROUP C-TETANUS TOXOID CONJUGATE VACCINE IN PRIMED TODDLERS 12 TO 18 MONTHS OF AGE. Pediatric Infectious Disease Journal, 2011, 30, 340-342.	1.1	14
165	Immunogenicity and Safety of an Investigational Combined Haemophilus influenzae Type B-Neisseria meningitidis Serogroups C and Y-Tetanus Toxoid Conjugate Vaccine. Pediatric Infectious Disease Journal, 2011, 30, 190-196.	1.1	26
166	Congenital and neonatal varicella: impact of the national varicella vaccination programme in Australia. Archives of Disease in Childhood, 2011, 96, 453-456.	1.0	50
167	Acellular Pertussis Vaccine at Birth and One Month Induces Antibody Responses By Two Months of Age. Pediatric Infectious Disease Journal, 2010, 29, 209-215.	1.1	96
168	Immunogenicity of a Monovalent 2009 Influenza A(H1N1) Vaccine in Infants and Children. JAMA - Journal of the American Medical Association, 2010, 303, 37.	3.8	181
169	Th2-polarisation of cellular immune memory to neonatal pertussis vaccination. Vaccine, 2010, 28, 2648-2652.	1.7	44
170	Long-term (5-year) antibody persistence following two- and three-dose regimens of a combined hepatitis A and B vaccine in children aged 1–11 years. Vaccine, 2010, 28, 4411-4415.	1.7	11
171	Primary and booster immunization with a diphtheria, tetanus, acellular pertussis, hepatitis B (DTPa–HBV) and Haemophilus influenzae type b (Hib) vaccine administered separately or together is safe and immunogenic. International Journal of Infectious Diseases, 2010, 14, e41-e49.	1.5	5
172	Varicella immunisation practice: Implications for provision of a recommended, nonâ€funded vaccine. Journal of Paediatrics and Child Health, 2009, 45, 297-303.	0.4	17
173	Safety of supplementing infant formula with long-chain polyunsaturated fatty acids and $\langle i \rangle$ Bifidobacterium lactis $\langle i \rangle$ in term infants: a randomised controlled trial. British Journal of Nutrition, 2009, 101, 1706-1713.	1.2	40
174	Pandemic Influenza and Community Preparedness. American Journal of Public Health, 2009, 99, S365-S371.	1.5	37
175	Safety and Immunogenicity of Concurrent Administration of Live Attenuated Influenza Vaccine With Measles-Mumps-Rubella and Varicella Vaccines to Infants 12 to 15 Months of Age. Pediatrics, 2008, 121, 508-516.	1.0	40
176	"l want the one for older women―— extending the human papillomavirus vaccine population base. Medical Journal of Australia, 2008, 189, 526-528.	0.8	2
177	A novel combined Haemophilus influenzae type b-Neisseria meningitidis serogroups C and Y-tetanus-toxoid conjugate vaccine is immunogenic and induces immune memory when co-administered with DTPa-HBV-IPV and conjugate pneumococcal vaccines in infants. Vaccine, 2007, 25, 8487-8499.	1.7	48
178	A cross-sectional survey to assess community attitudes to introduction of Human Papillomavirus vaccine. Australian and New Zealand Journal of Public Health, 2007, 31, 235-242.	0.8	89
179	DTPaâ€HBVâ€IPV vaccine for primary vaccination of infants. Journal of Paediatrics and Child Health, 2007, 43, 587-592.	0.4	7
180	Case for varicella surveillance in Australia. Journal of Paediatrics and Child Health, 2006, 42, 663-664.	0.4	8

#	Article	IF	CITATIONS
181	Uptake of varicella vaccine—a cross sectional survey of parental attitudes to nationally recommended but unfunded varicella immunisation. Vaccine, 2005, 23, 5389-5397.	1.7	34
182	Phase 2 Evaluation of Parainfluenza Type 3 Cold Passage Mutant 45 Live Attenuated Vaccine in Healthy Children 6–18 Months Old. Journal of Infectious Diseases, 2004, 189, 462-470.	1.9	53
183	Evaluation of Combined Live, Attenuated Respiratory Syncytial Virus and Parainfluenza 3 Virus Vaccines in Infants and Young Children. Journal of Infectious Diseases, 2004, 190, 2096-2103.	1.9	82
184	Paediatric Active Enhanced Disease Surveillance (PAEDS) annual report 2016: Prospective hospital-based surveillance for serious paediatric conditions. Communicable Diseases Intelligence (2018), 0, 43, .	0.3	15